Gilead Announces Sustained Virologic Response Rate of 78% from Phase 3 Study of Sofosbuvir
November 27, 2012 at 08:35 AM EST
Gilead Sciences (Nasdaq: GILD ) today announced topline results from the Phase 3 POSITRON study examining a 12-week course of once-daily sofosbuvir plus ribavirin (RBV) in patients with genotype 2 or 3 chronic hepatitis C virus (HCV) infection who are not candidates to take interferon (IFN). The study found that 78 percent of
